What serious adverse reactions happened during Parts 2 and 3?
The most common serious adverse reaction during Parts 2 and 3 was diarrhea.
The table below shows the serious adverse reactions that the study doctors
thought might be related to durvalumab or tremelimumab. It shows the serious
adverse reactions that happened in 2 or more participants in any group during
Parts 2 and 3. There were other serious adverse reactions, but these each
happened in only 1 participant in any treatment group.
Most common serious adverse reactions in Parts 2 and 3
Group 1 Group 2 Group 3 Group 4
Serious adverse (out of 101 (out of 74 (out of 69 (out of 82
reaction participants) participants) participants) participants)
Diarrhea 1.0% (1) 2.7% (2) 8.7% (6) 0.0% (0)
Abnormal liver
4.0% (4) 0.0% (0) 0.0% (0) 2.4% (2)
function
Inflammation of the
0.0% (0) 4.1% (3) 0.0% (0) 1.2% (1)
large intestine
Inflammation of the
pituitary gland, a
gland that releases 0.0% (0) 0.0% (0) 2.9% (2) 0.0% (0)
hormones into the
blood stream
Dehydration 0.0% (0) 2.7% (2) 0.0% (0) 0.0% (0)
Inflammation of the
pancreas due to the
0.0% (0) 0.0% (0) 0.0% (0) 2.4% (2)
bodyâ€™s own defence
system
22 | Clinical Study Results